Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ: ALVO )

12.77 -0.55 (-4.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 94,194
Open 13.30
Bid (Size) 5.110 (2)
Ask (Size) 15.15 (88)
Prev. Close 13.32
Today's Range 12.69 - 13.30
52wk Range 6.700 - 18.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe
From Alvotech
Via GlobeNewswire
Alvotech and STADA add to strategic alliance through denosumab partnership
From Alvotech
Via GlobeNewswire

Performance

YTD
+12.41%
+12.41%
1 Month
-8.72%
-8.72%
3 Month
+2.16%
+2.16%
6 Month
+13.61%
+13.61%
1 Year
+69.81%
+69.81%

More News

Read More
Alvotech Announces Strategic Refinancing Agreement
From Alvotech
Via GlobeNewswire
ALVO Stock Earnings: Alvotech Reported Results for Q4 2023
Via InvestorPlace
2 Generic Drug Makers With Growing Runways
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Alvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024
From Alvotech
Via GlobeNewswire
ALVO Stock Earnings: Alvotech Misses EPS for Q1 2024
Via InvestorPlace
Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Stocks Hold Steady On Mixed Fed Remarks, First Solar Rallies, Bitcoin Falls Below $70,000: What's Driving Markets Tuesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Alvotech and Dr. Reddy’s Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK
From Alvotech
Via GlobeNewswire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
From Alvotech
Via GlobeNewswire
Alvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)
From Alvotech
Via GlobeNewswire
Alvotech Announces Participation at BofA Securities Healthcare Conference 2024
From Alvotech
Via GlobeNewswire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
From Alvotech
Via GlobeNewswire
Fifth Third Bancorp Reports Upbeat Earnings, Joins Metropolitan Bank Holding, Paramount Global And Other Big Stocks Moving Higher On Friday
Via Benzinga
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Teva Pharmaceutical Industries Limited
Via Business Wire
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
From Alvotech
Via GlobeNewswire
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Alvotech Announces Increase in Number of Own Shares
From Alvotech
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.